EA023179B1 - Антитела против респираторного синцитиального вируса (pcb) и способы их применения - Google Patents
Антитела против респираторного синцитиального вируса (pcb) и способы их применения Download PDFInfo
- Publication number
- EA023179B1 EA023179B1 EA201200277A EA201200277A EA023179B1 EA 023179 B1 EA023179 B1 EA 023179B1 EA 201200277 A EA201200277 A EA 201200277A EA 201200277 A EA201200277 A EA 201200277A EA 023179 B1 EA023179 B1 EA 023179B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- antibodies
- rsv
- antigen
- antigen binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 241000711920 Human orthopneumovirus Species 0.000 title description 3
- 108091007433 antigens Proteins 0.000 claims abstract description 548
- 102000036639 antigens Human genes 0.000 claims abstract description 548
- 239000000427 antigen Substances 0.000 claims abstract description 547
- 230000027455 binding Effects 0.000 claims abstract description 546
- 239000012634 fragment Substances 0.000 claims abstract description 514
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 179
- 230000002265 prevention Effects 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 208000036142 Viral infection Diseases 0.000 claims abstract description 20
- 230000009385 viral infection Effects 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 402
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 364
- 229920001184 polypeptide Polymers 0.000 claims description 350
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 181
- 150000007523 nucleic acids Chemical class 0.000 claims description 140
- 102000039446 nucleic acids Human genes 0.000 claims description 135
- 108020004707 nucleic acids Proteins 0.000 claims description 135
- 150000001413 amino acids Chemical class 0.000 claims description 103
- 241000700605 Viruses Species 0.000 claims description 69
- 108060003951 Immunoglobulin Proteins 0.000 claims description 55
- 102000018358 immunoglobulin Human genes 0.000 claims description 55
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 50
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 230000000295 complement effect Effects 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 24
- 230000000840 anti-viral effect Effects 0.000 claims description 18
- 239000003443 antiviral agent Substances 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 241000342334 Human metapneumovirus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108091005703 transmembrane proteins Proteins 0.000 claims description 6
- 102000035160 transmembrane proteins Human genes 0.000 claims description 6
- 101100365490 Drosophila melanogaster Jon99Ci gene Proteins 0.000 claims description 5
- 230000004850 protein–protein interaction Effects 0.000 claims description 5
- 101150008449 ser3 gene Proteins 0.000 claims description 5
- 101100533231 Drosophila melanogaster Jon99Ciii gene Proteins 0.000 claims description 4
- 101150052146 SER2 gene Proteins 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 101100533228 Drosophila melanogaster Jon99Cii gene Proteins 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- 101150106567 ser1 gene Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 137
- 102000004169 proteins and genes Human genes 0.000 abstract description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 22
- 230000004927 fusion Effects 0.000 abstract description 18
- 230000001404 mediated effect Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 109
- 229940024606 amino acid Drugs 0.000 description 102
- 235000018102 proteins Nutrition 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 96
- 125000003729 nucleotide group Chemical group 0.000 description 74
- 239000002773 nucleotide Substances 0.000 description 65
- 230000000694 effects Effects 0.000 description 54
- 241000282414 Homo sapiens Species 0.000 description 45
- 239000000203 mixture Substances 0.000 description 43
- 230000001225 therapeutic effect Effects 0.000 description 38
- 230000003993 interaction Effects 0.000 description 35
- 102000040430 polynucleotide Human genes 0.000 description 34
- 108091033319 polynucleotide Proteins 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- -1 antibodies Proteins 0.000 description 33
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 32
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 32
- 101710177166 Phosphoprotein Proteins 0.000 description 32
- 239000008194 pharmaceutical composition Substances 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 28
- 102000053602 DNA Human genes 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 230000004048 modification Effects 0.000 description 27
- 238000012986 modification Methods 0.000 description 27
- 239000013615 primer Substances 0.000 description 27
- 230000006870 function Effects 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 239000012636 effector Substances 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 229920002477 rna polymer Polymers 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 230000002068 genetic effect Effects 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102100034349 Integrase Human genes 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 101710091045 Envelope protein Proteins 0.000 description 12
- 101710188315 Protein X Proteins 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 238000010494 dissociation reaction Methods 0.000 description 11
- 229940072221 immunoglobulins Drugs 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 230000005593 dissociations Effects 0.000 description 10
- 229960000402 palivizumab Drugs 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 108010089430 Phosphoproteins Proteins 0.000 description 9
- 102000007982 Phosphoproteins Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 238000010188 recombinant method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108010032595 Antibody Binding Sites Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 102100034574 P protein Human genes 0.000 description 7
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108060003393 Granulin Proteins 0.000 description 6
- 108060004795 Methyltransferase Proteins 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 239000005547 deoxyribonucleotide Substances 0.000 description 6
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 229910052745 lead Inorganic materials 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 101710104662 Enterotoxin type C-3 Proteins 0.000 description 5
- 102100030844 Exocyst complex component 1 Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 101710181008 P protein Proteins 0.000 description 5
- 101800004937 Protein C Proteins 0.000 description 5
- 102000017975 Protein C Human genes 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 101800001700 Saposin-D Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 229960000856 protein c Drugs 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 101150079036 rnc gene Proteins 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 4
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108091028664 Ribonucleotide Proteins 0.000 description 4
- 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 229960001521 motavizumab Drugs 0.000 description 4
- 244000309711 non-enveloped viruses Species 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 150000004713 phosphodiesters Chemical class 0.000 description 4
- 150000008300 phosphoramidites Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 239000002336 ribonucleotide Substances 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 101100172512 Mus musculus Epha2 gene Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 101710200413 Small hydrophobic protein Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 210000004507 artificial chromosome Anatomy 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710171457 Glycoprotein O Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- KAFGYXORACVKTE-UEDJBKKJSA-N chembl503567 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)C1=CC=C(O)C=C1 KAFGYXORACVKTE-UEDJBKKJSA-N 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000447 dimerizing effect Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- NWHMETIBESABNA-UHFFFAOYSA-N 1-[2-(7-azido-4-methyl-2-oxochromen-3-yl)acetyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1OC=2C=C(N=[N+]=[N-])C=CC=2C(C)=C1CC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O NWHMETIBESABNA-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIRFMIKBXCMIPE-UHFFFAOYSA-N 2,5-dioxo-1-[6-[[2-[1-(pyridin-2-yldisulfanyl)ethyl]benzoyl]amino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=C(C(=O)NCCCCCC(=O)ON2C(C(CC2=O)S(O)(=O)=O)=O)C=1C(C)SSC1=CC=CC=N1 IIRFMIKBXCMIPE-UHFFFAOYSA-N 0.000 description 1
- BDPOCFDNTVUOKD-UHFFFAOYSA-N 2-(7-azido-4-methyl-2-oxochromen-3-yl)acetamide Chemical compound C1=C(N=[N+]=[N-])C=CC2=C1OC(=O)C(CC(N)=O)=C2C BDPOCFDNTVUOKD-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
- 241000204432 Candidatus Sodalis pierantonius str. SOPE Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 101710146518 Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150096418 Mepe gene Proteins 0.000 description 1
- 101100445387 Mus musculus Ephb2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 241000690745 Neides Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000485664 Protortonia cacti Species 0.000 description 1
- 101000918244 Pseudoalteromonas phage PM2 Peptidoglycan hydrolase P7 Proteins 0.000 description 1
- 101000584831 Pseudoalteromonas phage PM2 Protein P6 Proteins 0.000 description 1
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010064250 RNA polymerase beta subunit Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 101150007309 SOK3 gene Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000000500 calorimetric titration Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000001730 gamma-ray spectroscopy Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000014670 posterior cortical atrophy Diseases 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000036273 reactive airway disease Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HHSGWIABCIVPJT-UHFFFAOYSA-M sodium;1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 HHSGWIABCIVPJT-UHFFFAOYSA-M 0.000 description 1
- ZAPNXDUFCQIHFS-UHFFFAOYSA-M sodium;2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ZAPNXDUFCQIHFS-UHFFFAOYSA-M 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27439509P | 2009-08-13 | 2009-08-13 | |
| PCT/US2010/045549 WO2011020079A1 (en) | 2009-08-13 | 2010-08-13 | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201200277A1 EA201200277A1 (ru) | 2012-09-28 |
| EA023179B1 true EA023179B1 (ru) | 2016-05-31 |
Family
ID=43014487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200277A EA023179B1 (ru) | 2009-08-13 | 2010-08-13 | Антитела против респираторного синцитиального вируса (pcb) и способы их применения |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8568719B2 (enExample) |
| EP (1) | EP2464664B1 (enExample) |
| JP (1) | JP5762408B2 (enExample) |
| KR (1) | KR101778317B1 (enExample) |
| CN (1) | CN102656189B (enExample) |
| BR (1) | BR112012003064B8 (enExample) |
| CA (1) | CA2770737C (enExample) |
| DK (1) | DK2464664T3 (enExample) |
| EA (1) | EA023179B1 (enExample) |
| ES (1) | ES2553440T3 (enExample) |
| IL (1) | IL217977A (enExample) |
| IN (1) | IN2012DN01328A (enExample) |
| MX (1) | MX2012001882A (enExample) |
| NZ (1) | NZ597996A (enExample) |
| PL (1) | PL2464664T3 (enExample) |
| SG (1) | SG178335A1 (enExample) |
| WO (1) | WO2011020079A1 (enExample) |
| ZA (1) | ZA201201007B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8568719B2 (en) | 2009-08-13 | 2013-10-29 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
| KR101896124B1 (ko) | 2010-07-09 | 2018-09-07 | 얀센 백신스 앤드 프리벤션 비.브이. | 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법 |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| HUE053545T2 (hu) | 2011-05-17 | 2021-07-28 | Univ Rockefeller | Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra |
| JP2014518080A (ja) * | 2011-06-27 | 2014-07-28 | バルネバ | 細胞のスクリーニング方法 |
| WO2013006544A1 (en) * | 2011-07-06 | 2013-01-10 | Medimmune, Llc | Methods for making multimeric polypeptides |
| TWI530505B (zh) * | 2011-12-27 | 2016-04-21 | 財團法人生物技術開發中心 | 輕鏈橋接型雙特異性抗體 |
| EP2825560A1 (en) * | 2012-03-13 | 2015-01-21 | Universiteit Utrecht Holding BV | Bi-specific adapters |
| KR102149069B1 (ko) * | 2012-03-20 | 2020-08-28 | 후맙스 바이오메드 에스에이 | Rsv, mpv 및 pvm를 중화하는 항체 및 이의 용도 |
| WO2014031174A1 (en) | 2012-08-24 | 2014-02-27 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| CN103048459B (zh) * | 2012-12-05 | 2014-08-20 | 中国科学院武汉病毒研究所 | 检测呼吸道合胞病毒的免疫检测试剂 |
| BR112015022790A8 (pt) | 2013-03-14 | 2020-01-21 | Univ Duke | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral |
| TWI659968B (zh) * | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AP2015008815A0 (en) | 2013-04-25 | 2015-10-31 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
| AP2015008893A0 (en) | 2013-06-17 | 2015-12-31 | Crucell Holland Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| ES2683169T3 (es) * | 2013-06-21 | 2018-09-25 | Alfresa Pharma Corporation | Dispositivo de inmunocromatografía para detectar el VRS |
| WO2015010792A1 (en) | 2013-07-24 | 2015-01-29 | Humabs Biomed Sa | Antibodies that potently neutralize rsv and uses thereof |
| EP3068417B1 (en) * | 2013-11-15 | 2023-12-27 | F. Hoffmann-La Roche AG | Methods for viral inactivation using eco-friendly detergents |
| CN103911389A (zh) * | 2014-04-09 | 2014-07-09 | 南昌大学 | 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法 |
| SG11201610446XA (en) | 2014-06-26 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| CN105319373B (zh) * | 2014-08-18 | 2017-01-18 | 董俊 | 基于磁性分离和量子点标记的人呼吸道合胞病毒快速检测方法和试剂盒 |
| SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| EP3204041A1 (en) * | 2014-10-10 | 2017-08-16 | Ablynx N.V. | Methods of treating rsv infections |
| CA2991156A1 (en) * | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infection |
| BR112017028449A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | polipeptídeos rsv f pré-fusão solúveis estabilizados |
| JP7189014B2 (ja) | 2015-07-07 | 2022-12-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
| CN106496324B (zh) * | 2015-11-30 | 2020-01-14 | 天津昊免生物技术有限公司 | 一种抗呼吸道合胞病毒的全人源抗体 |
| CN105542003B (zh) * | 2016-03-01 | 2019-12-06 | 苏州博泰神州生物技术有限公司 | 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体 |
| CN105753981B (zh) * | 2016-03-08 | 2019-10-08 | 湖北工业大学 | 抗人呼吸道合胞病毒n蛋白抗体及应用该抗体的免疫层析试剂盒 |
| CA3018139A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
| WO2017196970A1 (en) * | 2016-05-10 | 2017-11-16 | Georgia State University Research Foundation, Inc. | Heterocyclic derivatives for the thratment of rsv |
| BR112018074483A2 (pt) | 2016-05-30 | 2019-03-19 | Janssen Vaccines & Prevention B.V. | proteínas f do rsv pré-fusão estabilizadas |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| BR112019008063A2 (pt) * | 2016-10-21 | 2019-07-02 | Adimab Llc | anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso |
| WO2018150029A1 (en) * | 2017-02-17 | 2018-08-23 | Institut Pasteur | Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs) |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| KR20200053518A (ko) | 2017-09-15 | 2020-05-18 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 면역의 안전한 유도를 위한 방법 |
| SG11202104522UA (en) | 2018-11-13 | 2021-05-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| WO2020124846A1 (zh) * | 2018-12-18 | 2020-06-25 | 珠海泰诺麦博生物技术有限公司 | 抗呼吸道合胞病毒的中和抗体及其应用 |
| CL2018003869A1 (es) | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv |
| EP3969044A1 (en) | 2019-05-15 | 2022-03-23 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
| KR20220008816A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
| US20220308055A1 (en) * | 2019-08-27 | 2022-09-29 | University Of Central Florida Research Foundation, Inc. | Method and device for pathogen or antibody detection using unmodified signaling substances with or without unlabeled detection reagents |
| CN111166881B (zh) * | 2020-01-06 | 2023-03-24 | 国药中生生物技术研究院有限公司 | 一种重组呼吸道合胞病毒多表位嵌合疫苗及其制备方法和应用 |
| CA3177062A1 (en) | 2020-04-02 | 2021-10-07 | Janssen Vaccines & Prevention B.V. | Stabilized vaccine compositions |
| JP2023531554A (ja) | 2020-06-29 | 2023-07-24 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 呼吸器合胞体ウイルス感染に対するワクチンの組み合わせ |
| EP4204806A1 (en) * | 2020-08-31 | 2023-07-05 | Genentech, Inc. | Methods for producing antibodies |
| FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
| WO2022127793A1 (zh) * | 2020-12-18 | 2022-06-23 | 珠海泰诺麦博生物技术有限公司 | 呼吸道合胞病毒特异性结合分子 |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| CN113249333B (zh) * | 2021-03-16 | 2023-06-02 | 贵州省人民医院 | 一种分泌抗呼吸道合胞病毒单克隆抗体的杂交瘤细胞株rsvn4c3 |
| WO2022268120A1 (en) * | 2021-06-22 | 2022-12-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-rsv antibodies and uses thereof |
| EP4384535A4 (en) * | 2021-08-10 | 2025-06-25 | Icosavax, Inc. | Virus-like particle vaccine for respiratory syncytial virus |
| WO2025104604A1 (en) | 2023-11-14 | 2025-05-22 | Janssen Pharmaceuticals, Inc. | Anti-respiratory syncytial virus antibodies and uses thereof |
| CN117924472B (zh) * | 2024-02-04 | 2025-02-18 | 北京微星生物科技有限公司 | 针对呼吸道合胞病毒的抗体 |
| CN117964750B (zh) * | 2024-02-04 | 2024-10-25 | 北京微星生物科技有限公司 | 一种抗呼吸道合胞病毒的单克隆抗体及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106980A2 (en) * | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
Family Cites Families (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| SE459008B (sv) | 1986-09-04 | 1989-05-29 | Bioinvent Int Ab | Saett att framsstaella humana monoklonala antikroppar |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4997764A (en) | 1987-04-23 | 1991-03-05 | New York University | Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| SE461985B (sv) | 1988-09-13 | 1990-04-23 | Bioinvent Int Ab | In vitro immunisering av lymfocytinnehaallande cellpopulationer och materialsats daerfoer |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| NL8902087A (nl) | 1989-08-17 | 1991-03-18 | Stichting Tech Wetenschapp | Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten. |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| EP0434879A1 (en) | 1989-12-14 | 1991-07-03 | Schering-Plough | Method of making factor dependent human B cell lines |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| ES2223040T3 (es) | 1991-04-10 | 2005-02-16 | The Scripps Research Institute | Bibliotecas de receptor heterodimerilo que usan fagemidos. |
| WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| DE69231736T2 (de) | 1991-05-14 | 2001-10-25 | The Immune Response Corp., Carlsbad | Gerichtete abgabe von genen, die immunogene proteine kodieren |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DK0587738T3 (da) | 1991-06-05 | 2000-12-18 | Univ Connecticut | Destineret levering af gener, som koder for sekretionsproteiner |
| EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6685942B1 (en) | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| CA2144043C (en) | 1992-09-16 | 2005-01-18 | Dennis R. Burton | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| KR950703640A (ko) | 1992-10-09 | 1995-09-20 | 가일 케이,나우톤. | 간 보존 세포(liver reserve cells) |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5359681A (en) | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| EP1323346B1 (en) | 1995-01-17 | 2006-06-28 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5840300A (en) | 1995-09-11 | 1998-11-24 | Trustees Of The University Of Pennsylvania | Methods and compositions comprising single chain recombinant antibodies |
| DE69609188T2 (de) | 1995-09-18 | 2000-12-21 | Intracel Corp., Issaquah | Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020141990A1 (en) | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
| US5842307A (en) | 1996-11-15 | 1998-12-01 | May; Kenzel | Self-adjusting, automatic spot weed sprayer |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
| ES2172149T3 (es) | 1997-04-14 | 2002-09-16 | Micromet Ag | Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| DK1265928T3 (da) | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV-neutraliserende antistoffer med ultra høj affinitet |
| US20050175986A1 (en) | 2000-05-09 | 2005-08-11 | Smit Kline Beecham Corporation | Human monoclonal antibody |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| FR2817875B1 (fr) | 2000-12-07 | 2005-03-18 | Technopharm | Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
| SI1718677T1 (sl) | 2003-12-19 | 2012-08-31 | Genentech Inc | Monovalentni protitelesni fragmenti, uporabni kot zdravila |
| AU2005214988A1 (en) | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| DK1974020T3 (da) | 2005-12-16 | 2011-10-03 | Ribovax Biotechnologies Sa | Fremgangsmåde til at opnå immortaliserede antistofudskillende celler |
| BRPI0817079A2 (pt) | 2007-09-07 | 2016-10-11 | Symphogen As | processos para fabricação recombinante de anticorpos anti-rsv |
| US7867497B2 (en) | 2007-09-24 | 2011-01-11 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses therefor |
| US8568719B2 (en) | 2009-08-13 | 2013-10-29 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
| KR101896124B1 (ko) * | 2010-07-09 | 2018-09-07 | 얀센 백신스 앤드 프리벤션 비.브이. | 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법 |
-
2010
- 2010-08-13 US US12/806,498 patent/US8568719B2/en not_active Expired - Fee Related
- 2010-08-13 PL PL10747357T patent/PL2464664T3/pl unknown
- 2010-08-13 NZ NZ597996A patent/NZ597996A/en not_active IP Right Cessation
- 2010-08-13 DK DK10747357.1T patent/DK2464664T3/da active
- 2010-08-13 JP JP2012524926A patent/JP5762408B2/ja not_active Expired - Fee Related
- 2010-08-13 WO PCT/US2010/045549 patent/WO2011020079A1/en not_active Ceased
- 2010-08-13 EA EA201200277A patent/EA023179B1/ru not_active IP Right Cessation
- 2010-08-13 EP EP10747357.1A patent/EP2464664B1/en active Active
- 2010-08-13 CA CA2770737A patent/CA2770737C/en not_active Expired - Fee Related
- 2010-08-13 CN CN201080046058.XA patent/CN102656189B/zh not_active Expired - Fee Related
- 2010-08-13 SG SG2012009064A patent/SG178335A1/en unknown
- 2010-08-13 IN IN1328DEN2012 patent/IN2012DN01328A/en unknown
- 2010-08-13 ES ES10747357.1T patent/ES2553440T3/es active Active
- 2010-08-13 KR KR1020127006411A patent/KR101778317B1/ko not_active Expired - Fee Related
- 2010-08-13 BR BR112012003064A patent/BR112012003064B8/pt not_active IP Right Cessation
- 2010-08-13 MX MX2012001882A patent/MX2012001882A/es active IP Right Grant
-
2012
- 2012-02-07 IL IL217977A patent/IL217977A/en active IP Right Grant
- 2012-02-10 ZA ZA2012/01007A patent/ZA201201007B/en unknown
-
2013
- 2013-09-10 US US14/023,078 patent/US9365638B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106980A2 (en) * | 2007-03-06 | 2008-09-12 | Symphogen A/S | Recombinant antibodies for treatment of respiratory syncytial virus infections |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101778317B1 (ko) | 2017-09-13 |
| PL2464664T3 (pl) | 2016-02-29 |
| BR112012003064A2 (pt) | 2017-11-14 |
| CN102656189B (zh) | 2014-10-08 |
| US9365638B2 (en) | 2016-06-14 |
| CN102656189A (zh) | 2012-09-05 |
| DK2464664T3 (da) | 2016-01-18 |
| ZA201201007B (en) | 2019-08-28 |
| CA2770737A1 (en) | 2011-02-17 |
| IL217977A (en) | 2016-06-30 |
| WO2011020079A1 (en) | 2011-02-17 |
| CA2770737C (en) | 2020-05-12 |
| US20110076268A1 (en) | 2011-03-31 |
| NZ597996A (en) | 2014-02-28 |
| BR112012003064B8 (pt) | 2021-05-25 |
| SG178335A1 (en) | 2012-03-29 |
| AU2010282312A1 (en) | 2012-02-23 |
| MX2012001882A (es) | 2012-04-11 |
| JP5762408B2 (ja) | 2015-08-12 |
| JP2013501527A (ja) | 2013-01-17 |
| BR112012003064B1 (pt) | 2021-03-16 |
| ES2553440T3 (es) | 2015-12-09 |
| IN2012DN01328A (enExample) | 2015-06-05 |
| EP2464664B1 (en) | 2015-09-23 |
| EP2464664A1 (en) | 2012-06-20 |
| KR20120050480A (ko) | 2012-05-18 |
| EA201200277A1 (ru) | 2012-09-28 |
| US20140044719A1 (en) | 2014-02-13 |
| HK1172350A1 (zh) | 2013-04-19 |
| US8568719B2 (en) | 2013-10-29 |
| IL217977A0 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023179B1 (ru) | Антитела против респираторного синцитиального вируса (pcb) и способы их применения | |
| AU2017201306B2 (en) | Anti-human respiratory syncytial virus (RSV) antibodies and methods of use | |
| Xiao et al. | Development of a potent neutralizing nanobody against canine distemper virus hemagglutinin protein | |
| AU2010282312B2 (en) | Antibodies against human Respiratory Syncytial Virus (RSV) and methods of use | |
| WO2025024431A1 (en) | Broadly reactive antibodies to influenza b viruses | |
| HK1172350B (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| HK1181055A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| HK1181055B (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |